ArticlePLoS neglected tropical diseases2025
Schistosoma haematobium infection is associated with oncogenic gene expression in Cervical Mucosa, with enhanced effects following treatment: A pilot study.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundSchistosoma haematobium is a parasitic worm that infects over 110 million people worldwide, laying eggs that migrate into host urinary and reproductive tracts. While S. haematobium is a known carcinogen in the urinary bladder, its role in cervical cancer remains unclear and molecular effects of parasite eggs in genital tissue are largely unknown. Our objective was to characterize cervical transcriptional profiles in women with or without active S. haematobium infection and after anti-schistosome treatment.
methodsWe collected cervical cytobrush samples from women living in areas of Tanzania endemic for S. haematobium, before and 4-12 months after praziquantel treatment, and extracted RNA for transcriptome analysis. mRNA was isolated using poly(A) selection and sequencing was performed on an Illumina Hi-Seq4000 platform. Transcript alignment to the human hg19 reference genome and counting were accomplished using the HTSeq package. Genes were assessed for differential expression using DESeq2 and Limma. Ingenuity Pathway Analysis (IPA) was employed to identify gene networks altered in the presence of S. haematobium infection and following parasitological elimination of infection.
resultsAs part of this pilot study, we enrolled 20 participants with and 19 without S. haematobium infection. After adjusting for multiple comparisons, we identified 9 differentially expressed genes in women with versus without infection at baseline, 23 in women with parasitological clearance of infection post-treatment versus with infection at baseline, and 29 in those with parasitological elimination of infection versus without infection at baseline. Most differentially expressed genes were associated with heightened oncogenesis in both women with infection and in those with parasitological clearance of infection after treatment. Using IPA, we identified cancer-related networks and pathways in women with parasitological clearance compared to women with and without infection, as well as pathways involving inflammation and compromised epithelial integrity.
conclusionWomen with S. haematobium infection and those with recent parasitological clearance were found to have cervical gene alterations that have been reported in various cancers. Our findings suggest a possible increase in cervical cancer risk and susceptibility to secondary infections shortly after treatment. Further research is necessary to ascertain whether altered gene expression after parasitological clearance of S. haematobium resolves over time.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.